Analystreport

Rubius Therapeutics, Inc. (NASDAQ: RUBY) had its price target lowered by analysts at Guggenheim from $25.00 to $5.00.

Rubius Therapeutics, Inc.  (RUBY) 
Last rubius therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report